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Abstract: Olanzapine long-acting injection (OLAI) is a crystalline salt composed of olanzapine 
and pamoic acid, which permits a depot intramuscular formulation of olanzapine. The half-life of 
olanzapine pamoate is 30 days, and its steady state is reached approximately at 12 weeks. Oral 
supplementation of olanzapine is not required during OLAI initiation, according to Eli Lilly 
recommendations, although a study indicated that $60% of D2 receptor occupancy was reached 
only by the fifth injection cycle. To date, a short-term, placebo-controlled study of 8 weeks in 
acutely ill patients and a long-term, controlled trial of 24 weeks in stabilized patients have been 
conducted. In both the studies, efficacy and safety were similar to those of oral olanzapine, with 
the exception of an acute adverse effect, the so-called inadvertent intravascular injection event, 
which occurred 1–3 hours after the injection with an incidence rate of 0.07% per injection. It 
consisted of symptoms that are similar to those reported in cases of oral olanzapine overdose. 
The most significant studies published to date, on the use of olanzapine pamoate in schizophre-
nia, are reviewed in this article. The pharmacodynamic and pharmacokinetic profile and related 
side effects of OLAI are reported.
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Introduction
Schizophrenia is characterized by disorganized behavior and thought, positive (delu-
sions and hallucinations) and negative symptoms (eg, anhedonia, affective flattening, 
alogia, avolition) that induce dysfunction in many areas, such as interpersonal relations, 
work, and self-care,1,2 and, in most cases, progressive deterioration of personality and 
social skills.3 It is a chronic disorder with frequent exacerbations that often require 
hospitalization. Schizophrenia constitutes an economic burden for society due to both 
the patient’s inability to work and the need for assistance.4 To date, antipsychotic medi-
cation remains the cornerstone of current therapeutic interventions for schizophrenia, 
but approximately one-third of schizophrenic patients are treatment-resistant and 
approximately 50% of patients are noncompliant with antipsychotic treatment.5–6
Long-acting antipsychotic drugs
The first long-acting antipsychotic agents were developed in the 1960s in order to 
assure a constant delivery of the drug and to enhance therapeutic compliance.7 Using a 
long-acting antipsychotic drug may improve patient outcome by offering good efficacy 
and tolerability of an antipsychotic drug at the lowest effective dose without “  first-pass 
metabolism” and hematic peaks. Long-acting drug therapy also combines these 
pharmacological advantages with an improvement in therapeutic compliance since it Neuropsychiatric Disease and Treatment 2010:6 submit your manuscript | www.dovepress.com
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provides the opportunity for regular contacts between patient 
and therapeutic teams. Many data from clinical trials and 
meta-analyses show that long-acting antipsychotic treatments 
reduce relapses and hospitalizations and favor rehabilitation 
and psychosocial programs,8,9 which have a postive influence 
on such clinical outcomes as medication compliance, and 
symptom and relapse reduction.10
Conventional long-acting agents are associated with 
similar side effects to the equivalent oral doses of typical 
antipsychotic drugs, especially extrapyramidal symptoms and 
hyperprolactinemia. During the past 15 years, atypical antip-
sychotic agents have been introduced.11 The group of atypical 
antipsychotic drugs is heterogeneous but is characterized 
by similar clinical efficacy on both negative and cognitive 
symptoms with low risk of extrapyramidal side effects 
(EPS).12,13 Consequently, many patients were switched from 
conventional long-acting therapies to oral atypical antipsy-
chotic drugs, a practice that, interestingly, has never been 
evaluated scientifically.14
In 1997, the American Psychiatric Association guidelines 
for the treatment of patients with schizophrenia highlighted 
the need for a long-acting formulation of atypical antipsy-
chotic drugs and indicated 3 primary goals in the treatment of 
schizophrenia: (1) sustained relief from psychotic symptoms, 
(2) reduced relapse rates, and (3) improved functioning and 
quality of life.15
Long-acting injectable risperidone, constituted by biode-
gradable polymers, was the first available long-acting atypical 
antipsychotic drug. It is a newly developed intramuscular depot 
formulation of olanzapine, whose oral form was commercialized 
in 1996 in the United States; olanzapine pamoate was approved 
by US Food and Drug Administration (FDA) on November 12, 
2009 for adult patients affected by schizophrenia.
Methods
First, we review the pharmacodynamic profile and the effec-
tiveness of oral olanzapine according to the most relevant 
and recent studies, with the aim of highlighting the benefits 
and the risks of this drug, which has been largely used in a 
rapid-release formulation during the past 15 years. Then we 
analyze the chemical characteristics and pharmacokinetic 
profile of olanzapine pamoate, according to technical details of 
Eli Lilly, and positron emission tomography (PET) and plasma 
concentration studies. Then we describe the short- and long-
term clinical studies   conducted and published to date in order 
to define the   efficacy and safety profile of this new   formulation. 
We favord data published in scientific journals over those in 
poster and oral communications to congresses.
Data sources
Preclinical and clinical data were accessed by online search 
of the following web sites using the keywords “olanzap-
ine”, “depot”, “long-acting”, and “pamoate”: http://www.
pubmed.gov, www.tripdatabase.com, http://www.clinical-
trials.gov, http://www.embase.com, and http://www.nps.
org.au.
Pharmacodynamic profile  
of olanzapine
Olanzapine, a dibenzothiazepine structurally similar to clozap-
ine, shares higher affinity to 5-HT2A receptors than D2 receptors 
(high 5-HT2A/D2 ratio).11,16 In comparison to the other atypical 
neuroleptics, olanzapine presents high affinity for serotonin-
ergic 5-HT2A, 5-HT2C, 5-HT3, and 5-HT6 receptors,17 medium 
affinity for dopaminergic D1, D2, D3, D4, D5, and muscarinic 
M1–M5 receptors,18 low affinity for   adrenergic α1 and α2 recep-
tors, and the highest affinity for histamine H1 receptors (olan-
zapine is the most potent histamine H1 antagonist known).19,20 
Olanzapine selectively reduced the activity of dopaminergic 
mesolimbic (A10) neurons but not dopaminergic striatal (A9) 
neuron fire and, in animal studies, counteracted conditioned 
avoidance behavior (test of antipsychotic efficacy) at a dose 
that was not sufficient to induce catalepsy (test of motor 
side effect).21 More recently,   preclinical studies showed that 
olanzapine efficacy on   psychotic and cognitive symptoms of 
schizophrenia may be represented by its facilitating effect on 
N-methyl-D-aspartic acid, which can favor brain derived neu-
rotrophic factor (BDNF) expression.22,23 According to another 
study, treatment with olanzapine markedly restored the reduc-
tion of both BDNF and TrkB receptors in hippocampus, associ-
ated with previous treatment with haloperidol.24 Other studies 
mentioned that olanzapine efficacy on negative and depressive 
symptoms of schizophrenia might be related to inhibition 
of norepinephrine transporter25 and modulation of cytokine 
plasma level, as interleukin-2 declined after 8-week olanzapine 
treatment.26
Side effects of olanzapine
Olanzapine usually is a well-tolerated drug. Among its main 
side effects, bodyweight gain is the most significant, and it is 
especially marked in children and adolescents.27–29 Accord-
ing to data of Eli Lilly, the frequency of $7% bodyweight 
gain was 22.2% in adult patients and 40.6% in adolescent 
patients treated for a mean period of 47 days; during long-
term treatment with olanzapine of 21–48 weeks, the increase 
in bodyweight was more relevant.30 Olanzapine, like clo-
zapine but not conventional antipsychotic agents, increases Neuropsychiatric Disease and Treatment 2010:6 submit your manuscript | www.dovepress.com
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insulin release31,32 and induces a metabolic syndrome more 
frequently than the other first- or second-generation antip-
sychotic drugs, also in the acute treatment of first psychotic   
episode.33,34
EPS, including akathisia, can be induced only by high 
doses, whereas tardive dyskinesia can be improved by 
olanzapine treatment, as reported in some cases.35 Olan-
zapine rarely induces seizure or neuroleptic malignant 
syndrome.36
An influence on blood pressure, like hypotension, was 
observed only in the elderly (.65 years),30 and myocardial 
conduction alterations were rarely observed during olan-
zapine treatment.37 Although olanzapine possesses direct 
cardiac electrophysiological effects similar to those of 
class III antiarrhythmic drugs, it is less potent than other 
antipsychotic drugs (haloperidol, risperidone, sertindole) in 
lengthening the QT interval.38 Only under some conditions 
of impaired drug elimination, such as renal or hepatic insuf-
ficiency, coadministration of CYP1A2 substrate inhibitors 
or after drug overdose, could a QT-prolonging effect during 
olanzapine treatment be observed.39 Despite its affinity for 
muscarinic M1–M5 receptors shown in in vitro studies, its 
anticholinergic symptoms (dry mouth and constipation) are 
moderate. Olanzapine has a favorable profile in terms of pro-
lactin-sparing compared with first-generation antipsychotic 
drugs in adults but not in children and adolescents (a relevant 
prolactin elevation was observed in 47.4% of the pediatric   
population).30
Antipsychotic efficacy of olanzapine
Olanzapine effectiveness in the treatment of schizophrenia is 
indirectly shown by its extensive clinical use40 and is noted 
by many studies, and further confirmed by meta-analyses, 
such as that conducted by Davis et al,41 and large effective-
ness studies, such as the Clinical Antipsychotic Trials of 
Intervention Effectiveness (CATIE)42 and the European 
First Episode Schizophrenia Trial.43 Oral olanzapine has 
received regulatory approvals for the treatment of bipolar 
mania and, in combination with fluoxetine, for bipolar depres-
sion. A rapid-acting, nondepot intramuscular preparation 
of olanzapine is also available and approved for the treat-
ment of agitation associated with schizophrenia and bipolar   
mania.
The CATIE study42 found that olanzapine had the low-
est discontinuation rates compared with the other 5 antip-
sychotic drugs over the 18-month treatment period. In a 
meta-analysis including 16 studies, patients treated with 
olanzapine were found to have a lower all-cause discon-
tinuation rate than those treated with other antipsychotic 
drugs.44
Olanzapine pamoate monohydrate: 
chemical structure and 
pharmacokinetic profile
Olanzapine long-acting injection (OLAI) is a crystal-
line salt, whereas long-acting risperidone is a compound 
polymerized through a physical process in order to be 
slowly released, and conventional antipsychotic long-
acting injections (fluphenazine decanoate, haloperidol 
decanoate, perphenazine enanthate, zuclopentixol decano-
ate) are esterified compounds. OLAI is composed of 
olanzapine and pamoic acid in the form of micron-sized 
crystals suspended in water, which permits a depot intra-
muscular formulation of olanzapine.30 When injected into 
the muscle, the salt slowly dissolves and dissociates into 
separate molecules of olanzapine and pamoic acid at the 
site of injection; both these components enter into systemic 
circulation. The rate of dissolution of the crystalline salt is 
slow and regular, resulting in the absorption of olanzapine 
over a period of 4 weeks (steady state is approximately 
reached at 12 weeks). The oral supplementation of olan-
zapine is not required during OLAI initiation, according 
to Eli Lilly recommendations.30 The half-life of   olanzapine 
pamoate is 30 days (vs oral olanzapine 33 hours). The 
absorption and distribution of olanzapine pamoate are 
rapid and completed 6–8 months after the last injection. 
Ninety-three percent of olanzapine pamoate is bound 
to albumin and α1-acid-glycoprotein. In impaired renal 
functioning, a significant reduction of clearance and half-
life of oral olanzapine (57% of metabolized olanzapine 
is excreted into urine) is not observed, whereas in mild 
impaired hepatic functioning, both clearance (18 L/h) and 
half-life (39.3 hours) of oral olanzapine increased. OLAI 
has not been studied in these pathological situations, 
likewise in the elderly or in the pediatric and adolescent 
population, and it is not indicated for these conditions. 
Olanzapine is principally metabolized by CYP1A2, so 
that carbamazepine and cigarette smoke could induce its 
metabolism, but the reduction of olanzapine concentra-
tion when combined with these agents is clinically mild. 
Fluvoxamine and ciprofloxacin have shown a relevant 
inhibitor action on CYP1A2 olanzapine metabolism, 
increasing its hematic concentration. The pharmacokinetic 
variation related to gender and smokers is not superior to 
the inter-individual variability.30Neuropsychiatric Disease and Treatment 2010:6
Table 1 Doses of oral olanzapine and olanzapine pamoate and their 
plasma concentrations at steady state45
Oral olanzapine Olanzapine pamoate
Doses Plasma 
concentrations  
at steady state  
(ng/mL)
Doses Plasma  
concentrations   
at steady state  
(ng/mL)
10 mg/d 13–48 150 mg/2 wk 
300 mg/4 wk
5–41
15 mg/d 21–63 210 mg/2 wk 
405 mg/4 wk
8–51
20 mg/d 21–85 300 mg/2 wk 7–73
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
576
Di Lorenzo and Brogli
Olanzapine pamoate monohydrate: 
dose-finding studies
Plasma olanzapine concentrations were sampled periodically 
in a subset of 346 patients who had participated in a 24-week 
maintenance study of olanzapine pamoate in order to discover 
the equivalent dose to oral olanzapine (Table 1).45 
The percentage of patients who experienced relapse by 
24 weeks ranged from 1.5% (when switched from 10 mg/d 
oral olanzapine to 300 mg/2 wk of olanzapine pamoate) to 
18.8% (from 20 mg/d oral olanzapine to 150 mg/2 wk of 
olanzapine pamoate). In order to minimize the risk for exac-
erbation of psychosis, the authors recommended to start with 
the equivalent dose of olanzapine pamoate and then, 2 months 
later, to evaluate the maintenance dose, which would remain 
at 300 mg/2 wk for patients who had previously been stabi-
lized with 20 mg/d of oral olanzapine.
Oral olanzapine has shown a dose-dependent striatal 
D2 receptor occupancy of 60%–80% at usual clinical doses.46 
With the aim of determining whether the long-acting olan-
zapine pamoate depot provided sustained D2 receptor occu-
pancy, an open-label PET study was conducted in 14 patients 
(9 males, 5 females) with schizophrenia and schizoaffective 
disorder treated with an intramuscular injection of olanzapine 
pamoate 300 mg every 4 weeks for 6 months (6   injection 
cycles).47 During the first 4 injection cycles, 7 patients needed 
a supplementation with oral olanzapine due to the worsening 
of psychotic symptoms, as shown by the Brief Psychiatric 
Rating Scale (BPRS). No patients received an oral supple-
mentation at the time of PET scanning, which reflected only 
the OLAI D2 receptor occupancy. The need for oral olanzap-
ine supplementation decreased when occupancy with OLAI 
reached $60%, which represents a sufficient percentage for 
antipsychotic efficacy of most antipsychotic drugs. During the 
fifth injection cycle, the D2 receptor occupancy resembled the 
baseline occupancy level of oral olanzapine (84%). Dopamine 
D2 receptor occupancy and plasma olanzapine concentrations 
were significantly   correlated (r = 0.76; P = 0.001) during the 
6-month period. As suggested by the authors, these data could 
indicate that supplementation with oral olanzapine, or a higher 
dose (eg, 400 mg/4 wk) or an increased frequency of depot dos-
ing for the first 3 months, may be required to maintain adequate 
therapeutic response during the first injection cycles.47
Olanzapine pamoate:  
clinical studies
In order to conform to FDA requirements, the parent pharma-
ceutical company conducted 2 studies: a short-term, placebo-
controlled study48 and a long-term, controlled trial.49 
A third study of long-term treatment with olanzapine 
pamoate is available online (http://www.fda.gov), and has 
been reported in a review.50
Another long-term study (ClinicalTrials.gov Identifier: 
NCT00320489) of 2 years was completed in September 2009, 
but the results are not published yet. In this clinical trial, pri-
mary outcome measures consisted of the assessment of the 
difference between olanzapine pamoate (405 mg intramus-
cular followed 4 weeks later by 150–405 mg flexible dosing 
every 4 weeks for 96 weeks) and oral olanzapine (10 mg/d 
for 4 weeks followed by 5–20 mg flexible dosing, oral tablets, 
once daily, for 100 weeks) in time to all-cause discontinuation 
in outpatients with schizophrenia at risk for relapse.51
Data for OLAI comparison with other antipsychotic long-
acting injections are not available because, to date, such a 
study has not been conducted and comparison among results 
of different depot trials may be scientifically inaccurate.
Olanzapine pamoate: efficacy
1)  The first double-blind placebo-controlled study was 
conducted for a period of 8 weeks in acutely ill patients 
affected by schizophrenia.48 The primary efficacy measure 
was represented by mean change from baseline to end 
point in Positive and Negative Syndrome Scale (PANSS) 
total score. The second outcome was represented by 
change from baseline to end point in the Clinical Global 
Impression-Improvement (CGI-I) scale score. The acutely 
ill patients (n = 404) affected by schizophrenia were ran-
domly assigned to olanzapine pamoate of 300 mg/2 wk, 
405 mg/4 wk, and 210 mg/2 wk or placebo without any 
antipsychotic drug supplementation. All the 3 doses were 
found to be statistically significant superior to placebo 
(P , 0.001): the mean changes from baseline to end point 
in PANSS total score were −26.32, −22.57, and −22.49, 
respectively, compared with −8.51 for placebo. All the Neuropsychiatric Disease and Treatment 2010:6 submit your manuscript | www.dovepress.com
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3 doses induced a statistically significant difference 
from placebo at PANSS score by 7 days, but the doses 
300 mg/2 wk and 405 mg/4 wk induced a more rapid 
improvement at only 3 days from the starting of treat-
ment. All OLAI treatment groups showed a statistically 
significant improvement (P , 0.001) compared with 
placebo group at end-point CGI-I scale score (#3).
2)  A 24-week, double-blind randomized study, designed 
to assess the efficacy of olanzapine pamoate as 
maintenance treatment for outpatients affected by 
schizophrenia, investigated whether clinically stable 
patients already treated with other antipsychotic drugs 
would remain stable when switched to olanzapine   
pamoate.49
    Patients enrolled were first switched to open-label, oral 
olanzapine monotherapy over a period of 4–8 weeks. Only 
patients stabilized (n = 1065) for 4 consecutive weeks 
(no dose change of oral olanzapine, CGI-I = 4, BPRS 
positive symptom score = 4) were randomized to receive 
olanzapine pamoate at high dose (405 mg/4 wk), medium 
dose (300 mg/2 wk), low dose (150 mg/2 wk), very low 
dose (45 mg/4 wk), or to remain on their oral olanzapine 
up to 24 weeks. The first 3 doses of olanzapine pamoate 
corresponded to oral olanzapine 10, 15, and 20 mg, whereas 
the low subtherapeutic dose of 45 mg/4 wk was included 
as a comparator for the 3 therapeutic doses and could be 
considered a possible placebo equivalent. No supplemen-
tation with oral antipsychotic therapy was permitted after 
randomization. Two primary measures were rate and time of 
exacerbation. Exacerbation was defined as either the wors-
ening of positive symptoms (conceptual disorganization, 
hallucinatory behavior, suspicion, unusual thought content) 
at BPRS or the need for hospitalization due to the worsening 
of positive psychotic symptoms since randomization.
    At the end point, the 3 groups treated with therapeu-
tic doses of olanzapine pamoate showed a statistically 
significant superior period of time without psychotic 
exacerbation in comparison to the dose of 45 mg/4 wk 
(P , 0.001, P , 0.001, and P = 0.006, respectively). 
These observations were confirmed by the PANSS total 
scores, which showed that the 3 therapeutic doses of olan-
zapine pamoate were effective in maintaining a response 
throughout all the study periods, whereas the 45 mg/4 wk 
group showed a statistically significant worsening of total 
PANSS scores over the 24 weeks (P , 0.001). In addition, 
the noninferiority analysis demonstrated the equivalent 
efficacy of pooled 2-week depot doses (150 mg/2 wk and 
300 mg/2 wk) of oral olanzapine in terms of exacerbation 
rate after 24 weeks of maintenance treatment (the cumula-
tive nonexacerbation rate was 90% for the pooled 2-week 
regimen and 93% for the oral olanzapine group).
    The population (n = 1065) of this study was further 
  investigated in order to compare patients’ quality of life 
between oral and long-acting injectable formulations of 
olanzapine: clinician-rated and patient-reported outcomes 
were evaluated by means of the Heinrichs–Carpenter 
Quality of Life Scale (QLS), the Short Form Health Sur-
vey (SF36), and the Drug Attitude Inventory (DAI). Over 
the course of the 24-week study, subjects remained stable 
and experienced an increase in quality of life regardless 
of assignment to OLAI or oral olanzapine, suggesting a 
comparable effect of OLAI with equivalent doses of oral 
olanzapine on this parameter.52
    Adult patients with schizophrenia or schizoaffective 
disorder (n = 931), who participated in the 24-week 
study, were enrolled in an open-label extension trial of 
OLAI.53 At study onset, patients received flexibly dosed 
olanzapine LAI at intervals of approximately 2–4 weeks. 
After a period of 160 weeks, treatment response was 
measured by means of the Clinical Global Impression 
Severity of Illness (CGI-S) scale which showed a mean 
change of −0.16, from baseline score of 2.92, with a low 
discontinuation rate (39.6%).53
3)  A long-term, open-label study of 4 years was designed 
to assess the long-term efficacy and safety of olanzapine 
pamoate with doses ranging from 45 to 405 mg every 2 or 
4 weeks in patients with schizophrenia or schizoaffective 
disorder.50
    A total of 880 patients were included, and results showed 
that there was a statistically significant decrease in PANSS 
total score (P = 0.013) from 56.28 to 54.90 and CGI-Severity 
scores (range, 2.91–2.78), indicating patient improvement that 
remained stable throughout all periods of the study. The all-
cause discontinuation rate, a widely accepted measure of treat-
ment effectiveness, was found to be 34% at 18 months.50
Olanzapine pamoate: safety
Data of all patients (n = 1778, June 2006) treated with OLAI 
were collected from 2 controlled studies and 6 open-label 
studies (number of injections on average: 11.31) and were 
integrated in to a unique database.54 In this population, dis-
continuation rate was inferior to 6% due to adverse effects 
(weight gain, sedation/somnolence, and increased hepatic 
enzymes) or inefficient control of psychotic symptoms; 
3 deaths occurred that were not apparently related to the 
drug.Neuropsychiatric Disease and Treatment 2010:6 submit your manuscript | www.dovepress.com
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As shown in Table 2, in the short-term study,48 the 
incidence of bodyweight gain $7% of baseline was sig-
nificantly greater for all the olanzapine groups relative to 
placebo (P = 0.046). The increase in fasting total cholesterol 
was significantly higher in all patients treated with OLAI 
compared with placebo (P = 0.015) and, in particular, a sig-
nificant difference in fasting cholesterol was found between 
the patients treated with 210 mg/2 wk and 405 mg/4 wk 
(P = 0.16). Incidence of sedation and increased appetite were 
significantly higher for 300 mg/2 wk OLAI compared with 
placebo (P , 0.05).
As shown in Table 3, in the long-term study,49 bodyweight 
gain was significantlly greater for high dose than low dose 
(P = 0.04), but the incidence of weight gain $7% from the ran-
domization time in all the OLAI groups was not significantly 
different from that of the oral olanzapine groups. Patients in 
both OLAI and oral olanzapine groups had significantly higher 
levels of low-density lipoprotein and cholesterol relative to 
the comparative group (OLAI 45 mg/4 wk). The metabolic 
parameters (fasting glucose and lipid levels) of all OLAI 
groups overlapped those of oral olanzapine groups. Only 
the higher dose OLAI induced an increase of prolactin and a 
significantly higher level of triglycerides relative to the other 
doses of olanzapine pamoate. In this study, extrapyramidal 
and cardiovascular effects were not observed. Two patients 
experienced sedation and delirium consistent with inadvertent 
intravascular (IAIV) injection event.
These studies did not show any statistically significant 
difference in adverse events between oral olanzapine and the 
depot formulation, with the exception of a new potential safety 
risk that emerged in clinical trials, known as IAIV injection 
event, or postinjection delirium sedation syndrome (PDSS) 
as it was formerly defined, which initially led the FDA not to 
approve this preparation. This came to light when an unan-
ticipated degree of sedation was observed in a small number 
of patients after an injection. Although sedation is a common 
adverse effect in olanzapine treatments, the extent of sedation 
appeared relevant. As of September 30, 2007, 25 excessive 
sedation events were reported in 24 patients (1.2% of patients, 
0.07% of injections).54,55 As of May 31, 2008, the incidence of 
PDSS with olanzapine pamoate was 29 events in 28 patients, 
per .40,000 injections, for an incidence rate of 0.07% of 
injections.56
This adverse event consists of sedation, confusion, diz-
ziness, altered speech/dysarthria, and somnolence, symp-
toms that are consistent with those reported in case of oral 
olanzapine overdose. The severity of sedation ranged from 
  drowsiness to deep coma (2 cases of coma, 2 patients intu-
bated, 2 cases of delirium, and 2 cases of tonic-clonic convul-
sions were reported). In all the cases but one, who presented 
high blood pressure, the cardiovascular function remained 
unaltered. These effects usually occur within 1 hour of injec-
tion, but the median time ranged from 20 minutes to 3 hours 
postinjection. PDSS typically begins with milder symptoms 
(feeling of weakness, dizziness, irritability, or general mal-
aise), which can then progressively worsen (delirium, heavy 
sedation). Seventy-nine percent of patients who presented this 
adverse event needed to be hospitalized in order to observe 
and give them supportive medical care. To date, all patients 
have recovered fully from this adverse event, usually within 
3–72 hours, without permanent damage, and approximately 
70% of these continued to receive the depot injections.
Since an unpredictable pattern of IAIV injection events 
occurrence was observed, without any relationship with 
concomitant medications, substances, organic diseases or 
repeated OLAI injections, it has been hypothesized that a 
rapid release of free olanzapine into the bloodstream could 
Table 3 Metabolic side effects in a long-term study49 evaluated at the end point (24 weeks)
Treatment group Mean change 
from baseline  
(kg)
% patients with 
weight gain  
($7%)
% patients with  
increased triglycerides   
(.200 mg/dL)
45 mg/4 wk −0.95 8 3.4
150 mg/2 wk 0.67 15 6.5
405 mg/4 wk 0.89 16 9.8
300 mg/2 wk 1.70 21 24.5
Oral olanzapine  
(mean dose, 14.3 mg/d)
1.30 21 13.8
Table 2 Metabolic side effects in a short-term study48 evaluated 
at the end point (8 weeks)
Treatment  
group
% patients with  
weight gain ($7%)
% patients with  
increased triglycerides   
(.200 mg/dL)
Placebo 12.4 3.4
210 mg/2 wk 23.6 12.8
405 mg/4 wk 27.0 6.3
300 mg/2 wk 35.4 14.3Neuropsychiatric Disease and Treatment 2010:6 submit your manuscript | www.dovepress.com
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have occurred.57 Data on elevated plasma concentration of 
olanzapine measured during the event can confirm this hypoth-
esis. The solubility of olanzapine pamoate monohydrate in 
plasma is ∼167 times higher (0.5 mg/mL in plasma, 0.003 
mg/mL in aqueous buffer) than that in an aqueous medium. 
If the salt comes into contact with a considerable amount of 
blood or plasma, as occurs if the needle punctures a vessel or 
enters a rich capillary bed during administration, it dissolves 
more quickly, releasing free olanzapine. This dissolution can 
occur over a period of minutes to hours in the bloodstream, 
whereas when it takes place in muscle tissue, it requires a 
period of days to weeks. Other factors are believed to affect 
the dissolution rate of the pamoate salt, such as the amount 
of olanzapine pamoate suspension, the volume and rate of 
blood flow, and the degree of vascular injury secondary to 
injection. In order to decrease the risk of accessing a major 
nerve or blood vessel, the injection recommendations of 
OLAI should ensure that no blood is visible in the syringe 
after the aspiration for approximately 5 seconds and to place 
it deeply only into the gluteal muscle at a ventrogluteal site. 
Until now, data on OLAI injection in other parts of body, like 
deltoid muscle, are not available.56
Eli Lilly recommend a postinjection observation period of 
at least 1 hour up to 3 hours in a healthcare facility and require 
advising patients not to drive or operate heavy machinery 
and to be vigilant for signs and symptoms of potential IAIV 
injection events in the 24 hours after OLAI injection.
Conclusions
As highlighted by Citrome,57 olanzapine pamoate demon-
strated efficacy both in acutely ill and stabilized patients 
affected by schizophrenia, with low risk for extrapyramidal or 
vascular effects but high risk for metabolic syndrome. OLAI 
showed a pharmacological profile overlapping that of oral 
olanzapine, with the exception of a new acute adverse effect 
represented by an IAIV injection event, which has worried 
physicians and pharmacologists, delaying registration and 
clinical use of this new preparation. Although it has been 
interpreted as a type of acute overdose of olanzapine due to a 
relatively high hematic solubility of olanzapine pamoate salt, 
it could represent an unbalanced effect of this atypical antip-
sychotic agent due to its complex action on different central 
receptors. This effect has not yet been completely clarified. 
It could resemble the paradoxical worsening of psychotic 
symptoms which commonly occurs in some patients when 
optimal titration of an atypical antipsychotic drug has not been 
completely reached. We need to take account that evidence 
from clinical experience shows that a paradoxical excitement 
reaction with worsening of psychotic symptoms occurs dur-
ing the first 24 hours postinjection of a typical antipsychotic 
depot, according to the information referred to in the sheet of 
drugs, which could be interpreted as a sulpiride-like action of 
antipsychotic drugs that act as an antidepressant agent when 
their hematic concentration is very low. Nevertheless, this 
acute adverse effect has not been observed in such a severe 
clinical form during other long-acting antipsychotic treat-
ments probably for pharmacokinetic reasons: other typical 
antipsychotic depot are fat-soluble compounds with a slow 
dissolution rate and risperidone RP is a polymer compound 
that needs a long period of absorption. Only postmarketing 
data will indicate the real incidence and risk of OLAI IAIV 
injection event.
According to the pharmacokinetic profile (the   absorption 
of OLAI occurs over a period of 4 weeks and steady state is 
approximately reached at 12 weeks)30 and the D2 receptors 
occupancy data (only by the fifth injection cycle of 
300 mg/4 wk of OLAI, the D2 receptor occupancy resembled 
the baseline occupancy level of oral olanzapine),47 a supple-
mentation of oral olanzapine during the first injection cycle 
could be indicated in order to maintain a sufficient and 
stable hematic concentration, especially for patients who 
have previously required high doses of oral olanzapine. The 
prudent recommendation by the manufacturer, which does 
not advise any oral olanzapine supplementation, needs to be 
confirmed by real-world clinical use since the most severely 
affected patients are often excluded from controlled clinical 
trials because of ethical issues.
As cited above, nonadherence to treatment represents one of 
the most important reasons for relapse in schizophrenia, which 
progressively favors the worsening of disease course and the dete-
rioration of patient skills. Unmedicated schizophrenia patients 
relapse at a rate of approximately 10% per month, whereas main-
tenance treatment with antipsychotic medications can reduce 
this rate dramatically.41 Consistent treatment can improve the 
patient’s quality of life and lead to an overall reduction in the cost 
of care,58 by preventing or delaying relapse, which, if repeated, 
could induce neuronal apoptosis, so favoring progressive clinical 
deterioration, according to some authors.59
As indicated by many authors,60 one of the best strategies 
to overcome poor compliance may be long-acting injection 
therapy, although to date it has not yet been well accepted by 
physicians probably due to the availability of only few typical 
antipsychotic drug depots and also because of personal resis-
tance that leads the physician to consider depot as a type of 
invasive instrument for a patient.61 If the   physician identifies 
poor compliance as a symptom of psychosis, they use depot Neuropsychiatric Disease and Treatment 2010:6 submit your manuscript | www.dovepress.com
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as a necessary therapeutic instrument to overcome it so that 
they can foster their relationship with the patient in order to 
support the patient in therapeutic and rehabilitation care.
The general safety profile of olanzapine pamoate, which is 
similar to that of oral olanzapine with a comparable low rate 
of neurological side effects, can further improve compliance 
and  adherence to treatment. The positive effect of   olanzapine 
on neurotrophic factors and its nonrelevant action on the 
  seizure threshold can support the use of this drug as an option 
for some clinical situations. Otherwise, in OLAI treatment, 
the risk for metabolic syndrome, which appeared related to 
the higher doses of olanzapine pamoate also in short-term 
treatment, can represent a severe side effect because it could 
predispose patients to a premature death, especially in chronic 
treatment, according to most studies.62–64
The availability of atypical antipsychotic depot, like 
olanzapine pamoate, permits maintenance treatment in non-
adherent therapy patients who have previously shown a good 
response only to these oral drugs, as in cases characterized by 
negative, cognitive, or depressive symptoms, which are not 
ameliorated by typical antipsychotic drugs. Because olanzap-
ine has demonstrated a good efficacy on affective symptoms 
the oral preparation has been approved for the treatment of 
bipolar mania, and, in combination with fluoxetine, for the 
treatment of bipolar depression. In future, if clinical studies 
confirm this indication, olanzapine pamoate might represent 
an important therapeutic option for bipolar disease, which is 
characterized by very low compliance.
Finally, many other postmarketing clinical trials sup-
ported by clinical experience are necessary to better identify 
the antipsychotic effectiveness of “an old drug in a new 
look”, such as olanzapine pamoate.
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